Orchid Pharma Q1 FY27 Results: Revenue Rs 304 Cr, PAT Rs 3 Cr

August 17, 2026
Posted by: Ankit Jaiswal
Category: Market

Orchid Pharma Q1 FY27: Revenue Rs 304 Cr (+75% YoY). PAT Rs 3 Cr (-78% YoY). Gross Profit Rs 3 Cr. Consolidated. CMP Rs 971.05 on Aug 14, 2026.

Quick Answer

Orchid Pharma Q1 FY27 results showed consolidated revenue of Rs 304 crore (+75% YoY) with pat of Rs 3 crore (-78% YoY) and gross profit of Rs 3 crore. Results announced on August 14, 2026.

Orchid Pharma Q1 FY27 results showed consolidated revenue at Rs 304 crore, compared to Rs 173 crore in Q1 FY26 — a +75% change. The company operates across its core business segments and reported these Q1 FY27 results on August 14, 2026.

The Orchid Pharma Q1 FY27 results showed gross profit of Rs 3 crore (-50% YoY) versus Rs 6 crore in Q1 FY26. The pat of Rs 3 crore (-78% YoY) versus Rs 14 crore reflects the overall operating and financial outcome for the quarter.

Click Here – Get Free Investment Predictions

Orchid Pharma Q1 FY27 Financial Highlights

Metric	Q1 FY27 (Rs Crore)	Q1 FY26 (Rs Crore)	YoY Change
Revenue	304	173	+75%
Gross Profit	3	6	-50%
PAT / PAT	3	14	-78%

Orchid Pharma Q1 FY27 Performance Analysis

Use the Univest Screener to track Orchid Pharma live financials and Q1 FY27 results

Orchid Pharma Q1 FY27 results showed revenue of Rs 304 crore (+75% YoY), reflecting the prevailing market conditions and the company’s operational execution across its primary business segments.

Gross Profit at Rs 3 crore (-50% YoY) in Orchid Pharma Q1 FY27 results captures the direct cost economics — input costs, manufacturing or service delivery expenses — relative to the revenue generated in Q1 FY27.

The pat of Rs 3 crore (-78% YoY) in Orchid Pharma Q1 FY27 results represents the bottom-line outcome after accounting for all operating expenses, other income, and below-gross-profit costs.

Investors should evaluate Orchid Pharma Q1 FY27 results in the context of industry growth rates, the company’s competitive position, cost structure, and management’s FY27 guidance to form a comprehensive investment view.

Key Business Factors in Q1 FY27

Revenue Performance

Orchid Pharma Q1 FY27 results show revenue of Rs 304 crore (+75% YoY). Revenue trend reflects sector demand dynamics, competitive intensity, and the company’s market positioning in Q1 FY27.

Margin and Cost Dynamics

Gross Profit of Rs 3 crore (-50% YoY) in Orchid Pharma Q1 FY27 results reflects input cost trends, pricing power, and operational efficiency in the quarter.

PAT Outcome

The pat of Rs 3 crore (-78% YoY) captures the overall financial performance including both operational results and non-operating income or charges in Q1 FY27 results.

Dividend Details

Orchid Pharma has not declared a dividend for Q1 FY27. Annual dividend consideration will depend on full-year FY27 performance.

FY27 Outlook

The FY27 outlook for Orchid Pharma will be shaped by the revenue and margin trajectory visible from Q1 FY27 results. Key factors include sector demand trends, input cost management, competitive dynamics, and management’s execution capability.

Investors should monitor Q2 FY27 results for confirmation of the trends observed in Orchid Pharma Q1 FY27 results, particularly regarding revenue growth sustainability and margin progression.

Orchid Pharma Stock Performance

Download the Univest iOS App or Univest Android App to track Orchid Pharma share price live and stay updated on quarterly results.

Orchid Pharma shares traded at Rs 971.05 on August 14, 2026. The stock’s movement reflects the market’s immediate assessment of Q1 FY27 results in the context of prevailing sector valuations and growth expectations.

Key Risks

Revenue Growth Sustainability

Maintaining or improving the revenue trajectory from Orchid Pharma Q1 FY27 results depends on sector demand, competitive dynamics, and successful business development initiatives.

Margin Management

Gross and net margin sustainability in Orchid Pharma Q1 FY27 results and subsequent quarters is subject to input cost trends, pricing competition, and operational efficiency.

Macro and Sector Risks

Broader macroeconomic conditions, interest rate trends, and sector-specific regulatory changes could impact Orchid Pharma’s earnings trajectory from Q1 FY27 results.

Conclusion

Orchid Pharma Q1 FY27 results show revenue of Rs 304 crore (+75% YoY) and pat of Rs 3 crore (-78% YoY) — reflecting the company’s operating performance for April to June 2026.

Investors should conduct detailed sector and company-specific analysis, assess management strategy and guidance, before making investment decisions. Consult a SEBI-registered financial advisor.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Orchid Pharma Q1 FY27 Results

When were Orchid Pharma Q1 FY27 results announced?

Ans. Orchid Pharma Q1 FY27 results were announced on August 14, 2026, covering the April to June 2026 quarter on a consolidated basis.

What was Orchid Pharma’s revenue in Q1 FY27?

Ans. Orchid Pharma reported consolidated revenue of Rs 304 crore in Q1 FY27, +75% from Rs 173 crore in Q1 FY26.

What was Orchid Pharma’s pat in Q1 FY27?

Ans. Orchid Pharma’s pat was Rs 3 crore in Q1 FY27, -78% from Rs 14 crore in Q1 FY26.

What drove Orchid Pharma’s Q1 FY27 performance?

Ans. Orchid Pharma Q1 FY27 results reflect the company’s sector positioning, operational execution, cost management, and prevailing market conditions in April-June 2026.

Did Orchid Pharma declare a dividend for Q1 FY27?

Ans. No dividend has been declared for Q1 FY27. Annual dividend prospects will depend on full-year FY27 earnings performance.

What is the outlook for Orchid Pharma after Q1 FY27 results?

Ans. The FY27 outlook depends on revenue and margin sustainability from Q1 FY27 results, sector demand trends, and management guidance for the rest of FY27.

Is Orchid Pharma a good investment after Q1 FY27 results?

Ans. Orchid Pharma Q1 FY27 results provide the latest financial update. Investors should assess sector positioning, valuation, and growth prospects before investing. Consult a SEBI-registered advisor.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.